Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Reduce” from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have received an average rating of “Reduce” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.

Several equities research analysts have recently commented on VTYX shares. Canaccord Genuity Group lowered Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $16.00 to $14.00 in a research note on Thursday, January 8th. Wells Fargo & Company restated an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Oppenheimer lowered Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 8th. Piper Sandler cut shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a research report on Thursday, January 8th. Finally, UBS Group reissued a “neutral” rating and issued a $14.00 target price (down previously from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th.

Ventyx Biosciences Stock Up 0.3%

Shares of NASDAQ:VTYX opened at $13.97 on Friday. The stock has a market cap of $1.00 billion, a P/E ratio of -9.31 and a beta of 1.25. Ventyx Biosciences has a 52-week low of $0.78 and a 52-week high of $25.00. The business has a fifty day moving average of $11.63 and a two-hundred day moving average of $7.27.

Insider Buying and Selling at Ventyx Biosciences

In related news, insider John Nuss sold 12,675 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This trade represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 14.49% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ventyx Biosciences during the fourth quarter worth $31,000. Hudson Bay Capital Management LP bought a new stake in shares of Ventyx Biosciences during the second quarter worth approximately $34,000. Engineers Gate Manager LP bought a new position in shares of Ventyx Biosciences during the second quarter worth $42,000. Persistent Asset Partners Ltd bought a new stake in shares of Ventyx Biosciences in the third quarter valued at about $51,000. Finally, Jump Financial LLC acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at approximately $53,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.